PharMerica serves bidder a poison pill

Share this article:

Just days after rejecting a $456 million purchase offer, the board at PharMerica Corp. adopted a poison-pill defense. The measure is intended to prevent Omnicare Inc. from obtaining control of PharMerica “in a manner or on terms that are not in the best interests of the company," according to the firm. The maneuver trades rights with PharMerica common stock. These rights would be exercisable should a person or group amass 15% or more of the company's common stock without board approval or announces a tender offer that attempts to do so. The companies are the two largest providers of pharmaceutical services in the long-term care sector.

Share this article:

More in Products

LeadingAge's CAST releases EHR matrix selection tool

LeadingAge's Center for Aging Services Technologies released its 2014 version of a tool to let long-term providers choose the best electronic health record for their facility.

New magnetic badges debut

New magnetic badges debut

Imprint Plus has introduced The Mighty Badge name badge kit, which allows users to create reusable but personalized badges.

Hollister Incorporated celebrates antibacterial foam dressing

Hollister Incorporated celebrates antibacterial foam dressing ...

Hollister Incorporated's new Hydrofera Blue Ready antibacterial foam dressing has been named a "Top 10 Innovation in Podiatry" according to the Podiatry Today journal, as well as a "Top Innovation ...